The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Open accessAbstract
IMPORTANCE: We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of CSF biomarkers, as compared with healthy controls, in a cohort of entirely untreated patients with Parkinson disease (PD) at the earliest stage of the disease studied so far. OBJECTIVE: To evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers (Aβ1-42, total tau [T-tau], tau phosphorylated at threonine 181 [P-tau181], and α-synuclein) in drug-naive patients with early PD and demographically matched healthy controls enrolled in the Parkinson's Progression Markers Initiative (PPMI) study. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of the initial 102 research volunteers (63 patients with PD and 39 healthy controls) of the PPMI cohort. MAIN OUTCOMES AND MEASURES: The CSF biomarkers were measured by INNO-BIA AlzBio3 immunoassay (Aβ1-42, T-tau, and P-tau181; Innogenetics Inc) or by enzyme-linked immunosorbent assay (α-synuclein). Clinical features including diagnosis, demographic characteristics, motor, neuropsychiatric, and cognitive assessments, and DaTscan were systematically assessed according to the PPMI study protocol. RESULTS: Slightly, but significantly, lower levels of Aβ1-42, T-tau, P-tau181, α-synuclein, and T-tau/Aβ1-42 were seen in subjects with PD compared with healthy controls but with a marked overlap between groups. Using multivariate regression analysis, we found that lower Aβ1-42 and P-tau181 levels were associated with PD diagnosis and that decreased CSF T-tau and α-synuclein were associated with increased motor severity. Notably, when we classified patients with PD by their motor phenotypes, lower CSF Aβ1-42 and P-tau181 concentrations were associated with the postural instability-gait disturbance-dominant phenotype but not with the tremor-dominant or intermediate phenotype. Finally, we found a significant correlation of the levels of α-synuclein with the levels of T-tau and P-tau181. CONCLUSIONS AND RELEVANCE: In this first report of CSF biomarkers in PPMI study subjects,we found that measures of CSF Aβ1-42, T-tau, P-tau181, and α-synuclein have prognostic and diagnostic potential in early-stage PD. Further investigations using the entire PPMI cohort will test the predictive performance of CSF biomarkers for PD progression
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007) · Brain · doi:10.1093/brain/awm111 · Cited by 934
Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
Lewis, S. J. G. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033530 · Cited by 551
Neuropathologic substrates of Parkinson disease dementia
Irwin, D. J., White, M. T., Toledo, J. B., Xie, S. X., Robinson, J. L., Van Deerlin, V., Lee, V. M. ‐., Leverenz, J. B., Montine, T. J., Duda, J. E., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23659 · Cited by 518
Self-citationDiagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Dementia and survival in Parkinson disease: A 12-year population study
Buter, T. C., van den Hout, A., Matthews, F. E., Larsen, J. P., Brayne, C., & Aarsland, D. (2008) · Neurology · doi:10.1212/01.wnl.0000306632.43729.24 · Cited by 451
Burn, D. J. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.081711 · Cited by 436
Changes in motor subtype and risk for incident dementia in Parkinson's disease
Alves, G., Larsen, J. P., Emre, M., Wentzel‐Larsen, T., & Aarsland, D. (2006) · Movement Disorders · doi:10.1002/mds.20897 · Cited by 434
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418
The heterogeneity of Parkinson's disease: Clinical and prognostic implications
Zetusky, W. J., Jankovic, J., & Pirozzolo, F. J. (1985) · Neurology · doi:10.1212/wnl.35.4.522 · Cited by 380
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., & Clark, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 378
Jensen, P. H., Hager, H., Nielsen, M. S., Højrup, P., Gliemann, J., & Jakes, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25481 · Cited by 377
A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease
Hughes, T. A., Ross, H. F., Musa, S., Bhattacherjee, S., Nathan, R. N., Mindham, R. H. S., & Spokes, E. G. S. (2000) · Neurology · doi:10.1212/wnl.54.8.1596 · Cited by 372
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · cited 1×
“CSF total protein, mean (SD) [95% CI], mg/dL 40 (12) [36-43] 46 (21) [40-51] .”
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., Soares, H., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 298
The association of incident dementia with mortality in PD
Levy, G., Tang, M.-X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., & Marder, K. (2002) · Neurology · doi:10.1212/01.wnl.0000036610.36834.e0 · Cited by 297
α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models
Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 275
Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 264
Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H., Anckarsäter, R., Andreasen, N., Zetterberg, H., Andreasson, U., & Blennow, K. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/986310 · Cited by 234
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., et al. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216
Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J. N., & Sidhu, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.06.017 · Cited by 211
Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates
Cummings, J. L. (1988) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198878800100106 · Cited by 206
Compta, Y., Martí, M. J., Ibarretxe‐Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., Ezquerra, M., Ríos, J., & Tolosa, E. (2009) · Movement Disorders · doi:10.1002/mds.22594 · Cited by 185
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · cited 1×
“CSF total protein, mean (SD) [95% CI], mg/dL 40 (12) [36-43] 46 (21) [40-51] .”
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182
Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1
Jin, J., Li, G. J., Davis, J., Zhu, D., Wang, Y., Pan, C., & Zhang, J. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600182-mcp200 · Cited by 179
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173
Vanderstichele, H., De Vreese, K., Blennow, K., Andreasen, N., Sindic, C., Ivanoiu, A., Hampel, H., Bürger, K., Parnetti, L., Lanari, A., et al. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.258 · Cited by 171
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P.-J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · cclm · doi:10.1515/cclm.2011.086 · Cited by 167
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 163
The effect of age of onset of PD on risk of dementia
Aarsland, D., Kvaløy, J. T., Andersen, K., Larsen, J. P., Tang, M. X., Lolk, A., Kragh-Sørensen, P., & Marder, K. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0234-8 · Cited by 162
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 145
Graham, J., & SAGAR, H. J. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1<10::aid-mds1005>3.0.co;2-4 · Cited by 140
Haggerty, T., Credle, J. J., Rodriguez, O. C., Wills, J., Oaks, A. W., Masliah, E., & Sidhu, A. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07660.x · Cited by 140
Schmidt, M. L., Martin, J. A., Lee, V. M. ‐., & Trojanowski, J. Q. (1996) · Acta Neuropathologica · doi:10.1007/s004010050454 · Cited by 138
Tauopathic Changes in the Striatum of A53T α-Synuclein Mutant Mouse Model of Parkinson's Disease
Wills, J., Credle, J. J., Haggerty, T., Lee, J., Oaks, A. W., & Sidhu, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017953 · Cited by 89
Cerebrospinal fluid amyloid- and phenotypic heterogeneity in de novo Parkinson's disease
Alves, G. W., Pedersen, K. F., Bloem, B. R., Blennow, K., Zetterberg, H., Borm, G. F., Dalaker, T. O., Beyer, M. K., Aarsland, D., Andréasson, U., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303808 · Cited by 68
Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J. M., Kornhuber, J., & Lewczuk, P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110212 · Cited by 56
(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Cited by
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.644 · Cited by 671
Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Fereshtehnejad, S.-M., Zeighami, Y., Dagher, A., & Postuma, R. B. (2017) · Brain · doi:10.1093/brain/awx118 · Cited by 613
Metadata
- Authors
- Kang, J.-H.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-08-26
- Volume
- 70
- Issue
- 10
- Pages
- 1277-87
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2134113727
- Cited by
- 367
- References
- 51
- FWCI
- 24.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.